Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
Goutam ChakrabortyNabeela Khan PatailRahim HiraniSubhiksha NandakumarYing Z MazzuYuki YoshikawaMohammad O AtiqLina E JehaneKonrad H StopsackGwo-Shu Mary LeeWassim AbidaMichael J MorrisLorelei A MucciDaniel DanilaPhilip W KantoffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This work suggests that SRC activation may be a potential mechanism of PARPi resistance and that treatment with SRC inhibitors may overcome this resistance. Our preclinical study demonstrates that combining PARPis and SRC inhibitors may be a promising therapeutic strategy for patients with BRCA2-null mCRPC.